• Finn Gustafsson, Dan Atar, Bertram Pitt, Faiez Zannad, Marc A Pfeffer, and participants in 10th Cardiovascular Clinical Trialists Workshop.
• Rigshospitalet, Department of Cardiology, University of Copenhagen, Copenhagen, Denmark. finng@dadlnet.dk
• Am. Heart J. 2010 Jun 1;159(6):937-43.

AbstractTrialists have an ethical and financial responsibility to plan and conduct clinical trials in a manner that will maximize the scientific knowledge gained from the trial. However, the amount of scientific information generated by randomized clinical trials in cardiovascular medicine is highly variable. Generation of trial databases and/or biobanks originating in large randomized clinical trials has successfully increased the knowledge obtained from those trials. At the 10th Cardiovascular Trialist Workshop, possibilities and pitfalls in designing and accessing clinical trial databases were discussed by a group of trialists. This review focuses on the arguments for conducting posttrial database studies and presents examples of studies in which posttrial knowledge generation has been substantial. Possible strategies to ensure successful trial database or biobank generation are discussed, in particular with respect to collaboration with the trial sponsor and to analytic pitfalls. The advantages of creating screening databases in conjunction with a given clinical trial are described; and finally, the potential for posttrial database studies to become a platform for training young scientists is outlined.Copyright 2010 Mosby, Inc. All rights reserved.

7 keywords...

hide…